1.集团经导管人工主动脉瓣膜系统Ken-Valve首年商业化实现稳健收入。Ken-Valve可适用于主动脉瓣反 流或合并狭窄，其产品设计及操作性能的优势使得术式快速在多层级医疗机构推广应用; 2.集团多个结构心介入类产品于海外开展收费临床植入，其研究成果和临床应用优势获得全球各大洲关 键意见领袖及专家的高度评价，可满足全球庞大的结构性心脏病长期未被满足的临床需求。 集团于2026年继续推动多条产品管线发展以及持续深化国际化战略布局，实现高速收入增长;并将于生 产、供应链、营销、运营管理等方面不断提升管理效率、降低运营成本，以实现长期发展战略目标。 健世科技-B(09877)发布公告，于2025年12月31日止年度，集团预期实现收入人民币约9000万至9200万 元，其他收入及收益人民币约1500万至1800万元，共计人民币约1.05亿至1.1亿元。 集团首个商业化年度即实现可观收入，主要归因于报告期间内： ...

格隆汇1月26日丨健世科技-B(09877.HK)宣布，于2025年12月31日止年度，集团预期实现收入人民币约 9000万至9200万元，其他收入及收益人民币约1500万至1800万元，共计人民币约1.05亿至1.10亿元。 集团首个商业化年度即实现可观收入，主要归因于报告期间内： 1.集团经导管人工主动脉瓣膜系统Ken-Valve首年商业化实现稳健收入。Ken-Valve可适用於主动脉瓣反 流或合并狭窄，其产品设计及操作性能的优势使得术式快速在多层级医疗机构推广应用； 2.集团多个结构心介入类产品於海外开展收费临床植入，其研究成果和临床应用优势获得全球各大洲关 键意见领袖及专家的高度评价，可满足全球庞大的结构性心脏病长期未被满足的临床需求。 集团于2026年继续推动多条产品管线发展以及持续深化国际化战略布局，实现高速收入增长；并将於生 产、供应链、营销、运营管理等方面不断提升管理效率、降低运营成本，以实现长期发展战略目标。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 內幕消息 本集團商業化首年年度收入預告 本公告乃由寧波健世科技股份有限公司（「本公司」，連 同 其 附 屬 公 司，統 稱「本 集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香 港法例第571章證券及期貨條例第XIVA部 刊 發。 本公司董事（「董 事」）會（「董事會」）欣 然 宣 佈，於2025年12月31日止年度（「報告期 間」），本 集 團 預 期 實 現 收 入 人 民 幣 約90百萬至92百 萬 元，其 他 收 入 及 收 益 人 民 幣 約15百萬至18百 萬 元，共 計 人 民 幣 約105百萬至110百 萬 ...

Core Viewpoint - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "original creators," supported by solid data and market performance [1]. Group 1: Industry Overview - China's pharmaceutical industry is the second largest globally, with innovative drugs accounting for approximately 30% of global research [1]. - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking historical highs [1]. - The increase in competitiveness and cost-effectiveness of Chinese pharmaceutical assets is driving the industry into a critical phase of "innovation realization + global layout" [1]. Group 2: Regional Development - Shanghai's Pudong district is becoming a core hub for the global market connection of China's biopharmaceutical industry, with significant achievements in innovative drug approvals and business development transactions [1]. - By 2025, Pudong has approved 4 CAR-T products (30% of the global total) and 7 Class 1 new drugs (14% of the national total), with business development transaction amounts reaching $20.4 billion (14% of the global total) [1]. Group 3: Competitive Advantages - Chinese innovative pharmaceutical companies are gaining a competitive edge in the global market due to their speed and cost-effectiveness, being able to advance drug discovery 2-3 times faster and recruit clinical trial patients 2-5 times faster than international counterparts [3]. - The cost per patient for clinical trials in China is only half that of Europe and the US [3]. Group 4: Business Development Collaborations - Companies like Maiwei Biopharma and Jinsai Pharmaceutical are forming significant overseas business development collaborations, enhancing China's global competitiveness in innovative drugs [3][5]. - Maiwei Biopharma has accelerated its business development efforts, securing exclusive licensing agreements for innovative therapies within months of initial meetings [3][4]. Group 5: Full-Chain Layout - A number of innovative pharmaceutical companies are rapidly constructing comprehensive overseas layouts covering research, registration, and sales, transitioning from "licensing out" to "commercialization abroad" [9]. - By 2024, Pudong is expected to have over 20 innovative drugs achieving commercial sales, with total sales exceeding 11.6 billion yuan [9]. Group 6: Source Innovation - The market consensus is that only companies with source innovation capabilities, quality business development potential, and global layout abilities can effectively meet global market demands and achieve high valuations [16]. - Companies like Jinfang Pharmaceutical are focusing on unique therapeutic areas and avoiding following trends, which positions them favorably in the global market [17]. Group 7: Industry Ecosystem - The rise of China's innovative pharmaceutical industry is attributed to years of policy guidance, technological accumulation, and capital cultivation, leading to a critical growth inflection point [21]. - The unique industrial atmosphere, quality talent pool, and complete industrial chain in Zhangjiang are considered core advantages for companies operating in the region [21][22]. Group 8: Future Outlook - The Pudong district is set to enhance its support for the biopharmaceutical industry, aiming to become a global hub for innovative drug launches and scientific entrepreneurship [23]. - The ongoing development of a differentiated industrial linkage pattern is expected to further support the growth of the life sciences industry in the region [23]. Group 9: Conclusion - The path of globalization for Chinese innovative drugs is deepening, supported by core industrial hubs like Pudong and the continuous upgrading of companies' innovation and internationalization capabilities [24].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 本月底法定/註冊股本總額： RMB 417,167,290 備註： 第 1 頁 共 11 頁 v 1.1.1 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 寧波健世科技股份有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 310,306,209 | RMB | | ...

寧波健世科技股份有限公司 章 程 2025年12月 | 則 | 3 | 第一章 | 總 | 經營宗旨和範圍 | 4 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 第二章 | 份 | 5 | | | | | | | | | | | | | 第三章 | 股 | 股份發行 | 5 | | | | | | | | | | | | 第一節 | 股份增減和回購 | 8 | | | | | | | | | | | | | 第二節 | 股份轉讓 | 9 | | | | | | | | | | | | | 第三節 | 股東和股東會 | 11 | | | | | | | | | | | | | 第四章 | 東 | | 11 | | | | | | | | | | | | 第一節 | 股 | 股東會的一般規定 | 15 | | | | | | | | | | | | 第二節 | 股東會的召集 | 21 | | | | | | | | | | | | | 第三節 | 股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 二零二五年第三次股東特別大會由董事會根據《中 華 人 民 共 和 國 公 司 法》、上 市 規 則 及 組 織 章 程 細 則 召 開，由 執 行 董 事 兼 首 席 執 行 官 潘 斐 先 生 主 持。全 體 董 事 親 身 或 透 過 電 子 方 式 出 席 二 零 二 五 年 第 三 次 股 東 特 別 大 會。 於 二 零 二 五 年 第 三 次 股 東 特 別 大 會 日 期，已 發 行 股 份 總 數（不 包 括 庫 存 股 份， 倘 有）為417,167,290股，包 括310,306,209股H股 及106,861,081股 非 上 市 股 份。賦 予 股 東權利出席二零二五年第三次股東特別大會並於會上就所提呈決議案投票贊 成或反對或放棄投票的股份總數為417,106,290股。出 席 二 零 二 五 年 第 三 次 股 東 特別大 ...

Core Viewpoint - The company has submitted a CE certification application for its transcatheter mitral valve repair (TMVr) system, JensClip, marking a significant step in its internationalization strategy [1] Group 1 - The JensClip system is the second product for which the company has submitted a CE certification application, following the transcatheter tricuspid valve replacement system, LuX-ValvePlus [1] - The submission of the CE certification is an important milestone for the company's growth and expansion in international markets [1]

Core Viewpoint - The company has submitted a CE certification application for its transcatheter mitral valve repair system, JensClip, marking a significant step in its internationalization strategy [1][2] Group 1: Product Development - JensClip is designed for the treatment of severe mitral regurgitation, featuring a user-friendly and reliable operation [1] - The device incorporates a claw-wedge mechanical locking design that allows for locking at any angle, ensuring stable and reliable coaptation of the leaflets [1] - The diamond-shaped valve clip design facilitates retrieval and repositioning, enhancing safety during the procedure [1] - The integrated detachment design aims to reduce potential operational risks during the detachment process, effectively shortening the operational time [1] Group 2: Clinical and Regulatory Progress - The one-year clinical follow-up results and challenging case applications of JensClip have been presented at major international academic conferences, demonstrating excellent safety and efficacy indicators [1] - The product has completed the registration application submission to the National Medical Products Administration in China and is currently under review [2] - JensClip has successfully commenced clinical applications overseas, with the company actively promoting the registration process to meet broad clinical needs [2]

Core Viewpoint - The company has submitted a CE certification application for its innovative transcatheter mitral valve repair system, JensClip, marking a significant step in its internationalization strategy [1][2] Group 1: Product Overview - JensClip is designed for the treatment of severe mitral regurgitation, featuring a user-friendly and reliable operation [1] - The device includes a claw-wedge mechanical locking design that allows for locking at any angle, ensuring stable and reliable coaptation of the leaflets [1] - The diamond-shaped valve clip design facilitates retrieval and repositioning, enhancing safety during the procedure [1] - The integrated separation design aims to reduce potential operational risks during the separation process, effectively shortening the operational time [1] Group 2: Clinical and Regulatory Progress - The one-year clinical follow-up results and challenging case applications of JensClip have been presented at major international conferences, demonstrating excellent safety and efficacy indicators [1] - In China, the product has completed the submission of its registration application to the National Medical Products Administration and is currently under review [2] - JensClip has successfully commenced clinical applications overseas, with the company actively promoting the registration process to meet broad clinical needs [2]